Methods for treating testicular and ovarian adrenal rest tumors

1. A method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a corticotropin-releasing factor type-1 (CRF 1 ) antagonist or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the subject has congenital adrenal hyperplasia (CAH).

3. The method of claim 1 , wherein the size of the tumors is reduced.

4. The method of claim 1 , wherein the number of the tumors is decreased.

5. The method of claim 1 , wherein both the size and the number of the tumors are reduced or decreased.

6. The method of claim 1 , wherein the CRF 1 antagonist comprises a compound having structural Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 and R 2 are independently ethyl or n-propyl;

R 3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy; and

R 4 is hydrogen, Br, R a R b N—, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,

R a and R b are independently hydrogen, C 1 -C 3 alkyl, H 2 NCH 2 CH 2 —,

(CH 3 ) 3 COC(O)NHCH 2 CH 2 —, or CH 3 CH 2 CH 2 NHCH 2 CH 2 —.

7. The method of claim 6 , wherein R 3 is Cl, Br, or methyl.

8. The method of claim 6 , wherein R 4 is Br, R a R b N—, pyridin-4-yl, morpholin-4-yl, or

9. The method of claim 6 , wherein R 4 is morpholin-4-yl or

10. The method of claim 6 , wherein R 4 is hydrogen, Br, R a R b N— and R a and R b are independently C 1 -C 3 alkyl.

11. The method of claim 6 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the CRF 1 antagonist, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 5 mg/day to about 100 mg/day to the subject.

13. The method of claim 1 , wherein the CRF 1 antagonist, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 10 mg/day to about 400 mg/day to the subject.

14. The method of claim 1 , wherein the CRF 1 antagonist, or a pharmaceutically acceptable salt thereof, is administered orally.

15. The method of claim 1 , wherein the CRF 1 antagonist, or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.

16. The method of claim 1 , further comprising administering to the subject an additional chemotherapeutic agent.

17. The method of claim 16 , wherein the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen.

18. The method of claim 17 , wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.

19. The method of claim 6 , wherein R 3 is Cl, Br, methyl, or trifluoromethyl.